BBNX
Beta Bionics, Inc. NASDAQ Listed Jan 30, 2025$13.67
-0.22%
vs $13.70
Mkt Cap $554.0M
52w Low $8.86
20.8% of range
52w High $31.99
50d MA $11.79
200d MA $18.40
P/E (TTM)
-9.1x
EV/EBITDA
—
P/B
1.9x
Debt/Equity
0.0x
ROE
—
P/FCF
—
RSI (14)
56.90
ATR (14)
$1.00
Beta
5.06
50d MA
$11.79
200d MA
$18.40
Avg Volume
902.7K
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
CIK (SEC)
Phone
949 427 7785
11 Hughes · Irvine, CA 92618 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21, 2026 | AMC | -0.53 | -0.49 | +7.5% | 12.27 | +5.6% | -0.6% | -6.3% | -2.3% | -4.7% | -5.4% | — |
| Feb 17, 2026 | AMC | -0.42 | -0.30 | +28.6% | 13.97 | -7.7% | -2.6% | -1.1% | +1.8% | +0.4% | -2.7% | — |
| Oct 28, 2025 | AMC | -0.45 | -0.33 | +26.7% | 24.28 | +15.7% | +10.3% | -0.0% | +1.6% | +1.8% | +0.4% | — |
| Jul 29, 2025 | AMC | -0.51 | -0.39 | +23.5% | 14.66 | +3.0% | +14.3% | +0.2% | -2.3% | +0.1% | -3.7% | — |
| May 6, 2025 | AMC | -0.51 | -0.52 | -2.0% | 11.35 | +4.9% | +26.6% | +3.8% | -6.4% | +1.6% | -6.9% | — |
| Mar 25, 2025 | AMC | -0.42 | -1.82 | -333.3% | 15.22 | -4.3% | -13.6% | -3.7% | -7.6% | +4.5% | -8.2% | — |
| Jan 31, 2025 | AMC | — | -1.55 | — | 23.81 | +0.8% | -4.5% | +1.1% | -0.7% | +2.8% | +0.1% | — |
| Dec 31, 2023 | AMC | — | -3.13 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -1.71 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Stifel | Maintains | Buy → Buy | — | $12.27 | $12.96 | +5.6% | -0.6% | -6.3% | -2.3% | -4.7% | -5.4% |
| Apr 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $12.27 | $12.96 | +5.6% | -0.6% | -6.3% | -2.3% | -4.7% | -5.4% |
| Apr 15 | Truist | Maintains | Buy → Buy | — | $11.81 | $11.51 | -2.5% | +10.2% | -6.5% | +6.6% | -0.5% | -5.0% |
| Apr 9 | Goldman Sachs | Maintains | Buy → Buy | — | $9.79 | $9.67 | -1.2% | -1.6% | -8.0% | +20.0% | +11.1% | +10.2% |
| Feb 18 | Baird | Maintains | Neutral → Neutral | — | $13.97 | $12.89 | -7.7% | -2.6% | -1.1% | +1.8% | +0.4% | -2.7% |
| Feb 18 | Stifel | Maintains | Buy → Buy | — | $13.97 | $12.89 | -7.7% | -2.6% | -1.1% | +1.8% | +0.4% | -2.7% |
| Feb 4 | Stifel | Maintains | Buy → Buy | — | $14.46 | $14.46 | +0.0% | -2.6% | -6.0% | -1.2% | +6.0% | +6.6% |
| Feb 2 | Truist | Maintains | Buy → Buy | — | $13.83 | $13.71 | -0.9% | -0.9% | +5.5% | -2.6% | -6.0% | -1.2% |
| Jan 9 | Lake Street | Maintains | Buy → Buy | — | $31.99 | $22.75 | -28.9% | -37.0% | -12.4% | -2.2% | -1.6% | +4.7% |
| Jan 5 | BofA Securities | Maintains | Buy → Buy | — | $29.25 | $29.25 | +0.0% | +1.1% | +6.2% | +0.3% | +1.6% | -37.0% |
| Dec 18 | Truist | Maintains | Buy → Buy | — | $29.19 | $30.05 | +2.9% | -0.4% | +0.7% | +8.3% | -1.1% | -0.8% |
| Oct 29 | Goldman Sachs | Maintains | Buy → Buy | — | $24.28 | $28.10 | +15.7% | +10.3% | -0.0% | +1.6% | +1.8% | +0.4% |
| Oct 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $24.28 | $28.10 | +15.7% | +10.3% | -0.0% | +1.6% | +1.8% | +0.4% |
| Oct 29 | Stifel | Maintains | Buy → Buy | — | $24.28 | $28.10 | +15.7% | +10.3% | -0.0% | +1.6% | +1.8% | +0.4% |
| Oct 29 | Truist | Maintains | Buy → Buy | — | $24.28 | $28.10 | +15.7% | +10.3% | -0.0% | +1.6% | +1.8% | +0.4% |
| Oct 1 | Goldman Sachs | Upgrade | Neutral → Buy | — | $19.87 | $21.00 | +5.7% | +1.7% | +1.4% | +8.6% | -1.4% | +0.9% |
| Sep 22 | Truist | Maintains | Buy → Buy | — | $22.46 | $22.68 | +1.0% | +2.0% | -0.1% | -0.6% | -2.6% | -11.7% |
| Jul 30 | Truist | Maintains | Buy → Buy | — | $14.66 | $15.10 | +3.0% | +14.3% | +0.2% | -2.3% | +0.1% | -3.7% |
| Jul 30 | Baird | Maintains | Neutral → Neutral | — | $14.66 | $15.10 | +3.0% | +14.3% | +0.2% | -2.3% | +0.1% | -3.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | Hopman Mark | Chief Commercial Officer | Sell | 5,329 | $12.61 | $67K | 130,887 | +11.57% | -4.66% |
| Jun 2, 2026 | Mensinger Mike | Chief Product Officer | Sell | 4,378 | $12.61 | $55K | 184,415 | +11.57% | -4.66% |
| Jun 2, 2026 | Feider Stephen | Chief Financial Officer | Sell | 6,676 | $12.61 | $84K | 166,053 | +11.57% | -4.66% |
| Jun 2, 2026 | Saint Sean | President & CEO | Sell | 16,872 | $12.61 | $213K | 420,937 | +11.57% | -4.66% |
| Jun 2, 2026 | Russell Steven Jon | Chief Medical Officer | Sell | 4,222 | $12.61 | $53K | 173,849 | +11.57% | -4.66% |
| May 22, 2026 | Lezack Adam | — | Sell | 998 | $11.21 | $11K | 27,399 | -0.77% | -0.08% |
| May 21, 2026 | Lezack Adam | — | Sell | 1,000 | $9.95 | $10K | 11,432 | -0.77% | -0.08% |
| May 21, 2026 | Jones Christy | — | Sell | 1,998 | $9.95 | $20K | 13,246 | -0.77% | -0.08% |
8-K · 8.01
!! High
Beta Bionics, Inc. -- 8-K 8.01: Material Event / Announcement
May 21
8-K
Beta Bionics, Inc. -- 8-K Filing
Beta Bionics raised its full-year 2026 guidance after beating first-quarter expectations, signaling improved operational performance and investor confidence in its diabetes management solutions business.
Apr 21
8-K
Beta Bionics, Inc. -- 8-K Filing
Beta Bionics reported 2025 financial results and provided 2026 guidance, signaling management confidence in the diabetes management solutions company's forward trajectory.
Feb 17
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 6,918,906 | $211M | Reduced | Dec 2025 |
| 2 | Soleus Capital Management, L.p. | 4,354,501 | $44M | Added | Mar 2026 |
| 3 | Sands Capital Alternatives, Llc | 3,708,043 | $37M | Added | Mar 2026 |
| 4 | Farallon Capital Management Llc | 3,607,920 | $36M | New | Mar 2026 |
| 5 | Point72 Asset Management | 2,525,040 | $25M | Added | Mar 2026 |
| 6 | Rtw Investments, Lp | 2,000,000 | $20M | Reduced | Mar 2026 |
| 7 | Vanguard Capital Management Llc | 1,727,977 | $17M | New | Mar 2026 |
| 8 | Deerfield Management Company, L.p. | 1,324,000 | $13M | Added | Mar 2026 |
| 9 | Millennium Management | 860,866 | $9M | Reduced | Mar 2026 |
| 10 | Ubs Group Ag | 623,253 | $6M | Added | Mar 2026 |
| 11 | Bruce & Co., Inc. | 550,700 | $6M | New | Mar 2026 |
| 12 | Healthcare Of Ontario Pension Plan Trust Fund | 546,132 | $5M | Reduced | Mar 2026 |
| 13 | Y-Intercept (Hong Kong) Ltd | 485,854 | $5M | Added | Mar 2026 |
| 14 | First Eagle Investment Management, Llc | 484,000 | $5M | Reduced | Mar 2026 |
| 15 | Jane Street Group, Llc | 140,592 | $4M | Added | Dec 2025 |
| 16 | Jpmorgan Chase & Co | 307,229 | $3M | Reduced | Mar 2026 |
| 17 | Northern Trust Corp | 295,818 | $3M | Added | Mar 2026 |
| 18 | Vanguard Portfolio Management Llc | 229,042 | $2M | New | Mar 2026 |
| 19 | Tudor Investment Corp | 218,094 | $2M | New | Mar 2026 |
| 20 | Raymond James Financial Inc | 188,883 | $2M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$554.0M
Enterprise Value
$334.9M
P/E (TTM)
-9.05x
Forward P/E
—
PEG Ratio
0.21x
P/B
1.93x
P/S
5.03x
P/FCF
—
EV/EBITDA
—
Shares Out
40.5M
Financials (TTM)
Revenue
$110.2M
Net Income
-$66.4M
EBITDA
-$63.5M
Free Cash Flow
$0
Op Cash Flow
$0
EPS Basic
$-1.81
EPS Diluted
$-1.51
EPS Forward
$-2.20
Gross Margin
57.1%
Op Margin
-70.1%
Net Margin
-60.3%
Balance Sheet
Total Assets
$328.7M
Total Liab.
$41.1M
Total Equity
$287.6M
Cash
$219.1M
LT Debt
$0
Book Value/Sh
$7.10
Debt/Equity
0.04x
Current Ratio
8.66
Quick Ratio
7.96
Returns & Growth
ROE
—
ROA
—
ROIC
-23.9%
Rev Growth YoY
+53.9%
EPS Growth YoY
+79.0%
Price Returns
2W
+31.7%
1M
+18.8%
3M
-4.0%
6M
-61.3%
12M
-29.7%
Technicals
52W High
$31.99
52W Low
$8.86
50d MA
$11.79
200d MA
$18.40
RSI (14)
56.90
ATR (14)
$1.00
Beta
5.06
Avg Volume
903K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$21.00
High
$25.00
Low
$14.00
Median
$22.00
Data updated apr 24, 2026 8:43pm
· Source: financialmodelingprep.com